Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics PLC has announced a promising interim report, highlighting a $10 million out-licensing deal for its Midkine antibody program and significant progress in its pre-clinical portfolio. The company has also implemented cost-cutting measures and secured funding to ensure operations for the next year. With several patents granted and a UK R&D refund received, Roquefort Therapeutics is actively pursuing further therapeutic licensing deals and is confident in establishing additional partnerships.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
